Growing Optimism for Newly Diagnosed Myeloma/High-Risk Disease: MCRT Interactive Webcast on November 21
Growing Optimism for Newly Diagnosed Myeloma/High-Risk Disease: MCRT Interactive Webcast on November 21 image
Nov 21, 2020 / 11:00AM - 04:15PM EST
HealthTree Round Tables for Multiple Myeloma Chapter

Event Description

Choose to attend one or both of two 2 1/2 hour sessions, one registration covers both sessions.The faculty for the first session of the Myeloma Crowd Round Table Interactive Webcast will explain “Why We’re Optimistic About Newly Diagnosed Myeloma.” Fear, uncertainty, and pessimism accompany virtually every cancer diagnosis, especially if most patients, like those with myeloma, have never even heard the word before. Yet myeloma specialists are increasingly confident and optimistic that the vast majority of diagnosed patients have legitimate paths toward longevity, good quality of life, and will benefit from increasing treatment options and experience. High-risk disease, the focus of the second session, poses the most difficult questions in myeloma treatment. Increasing knowledge about genetic differentiation provides information about which features to target and treat. And although most new medications are generally approved for patients who have had many lines of treatment, they are increasingly being used as front-line treatments for high-risk disease patients with encouraging results. These and other topics will be discussed by the faculty.

Schedule & Agenda

person
Session One: Why We’re Optimistic About Newly Diagnosed Myeloma
11:00AM
Jennifer Ahlstrom, Founder and President
Welcome and Introduction
person
Session One: Why We’re Optimistic About Newly Diagnosed Myeloma
11:05AM
Leif Bergsagel, MD, Mayo Clinic
An overview of the history of progress in myeloma research and treatment.
person
Session One: Why We’re Optimistic About Newly Diagnosed Myeloma
11:25AM
Matthew Fero, MD, FACP, University of New Mexico Comprehensive Cancer Center
Therapeutic options available to newly diagnosed patients.
person
Session One: Why We’re Optimistic About Newly Diagnosed Myeloma
11:45AM
Edward Libby, MD, Seattle Cancer Care Alliance
How patients should balance their expectations today with those in the foreseeable future.
person
Session One: Why We’re Optimistic About Newly Diagnosed Myeloma
12:05PM
Sarah Lee, MD, Seattle Cancer Care Alliance
A moderated discussion with two case studies.
person
Session One: Why We’re Optimistic About Newly Diagnosed Myeloma
12:25PM
Full Faculty
Audience Questions & Answers
person
Myeloma Coach Program
01:30PM
Rozalynn Hite, Program Director
An overview of the Myeloma Coach Program
person
Session Two: High-Risk Disease
01:40PM
Jennifer Ahlstrom, Founder and President
Welcome and Introduction of Faculty
person
Session Two: High-Risk Disease
01:45PM
Sarah Holstein, MD, PhD, University of Nebraska Medical Center
An overview of the current state of knowledge about high-risk disease.
person
Session Two: High-Risk Disease
02:05PM
Parameswaran Hari, MD, MS, Medical College of Wisconsin
The range of treatment options available for high-risk disease.
person
Session Two: High-Risk Disease
02:25PM
Andrew Cowan, MD, Seattle Cancer Care Alliance
Emerging therapeutic options that give physicians greater optimism about treating high-risk disease.
person
Session Two: High-Risk Disease
02:45PM
David Coffey, MD, Seattle Cancer Care Alliance
A moderated discussion with two case studies.
person
Session Two: High-Risk Disease
03:05PM
Full Faculty
Audience Questions & Answers
person
Session Two: High-Risk Disease
04:10PM
Jennifer Ahlstrom, Founder and President
Closing

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Read Bio
The panelist Rozalynn Hite
Rozalynn Hite

Rozalynn Hite is the Myeloma Coach Director and wife of myeloma patient Richard Hite. Rozalynn is an occupational therapist and mother of three beautiful children.

Read Bio
The panelist Greg Brozeit
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Read Bio
The panelist Leif Bergsagel, MD
Leif Bergsagel, MD

Leif Bergsagel, MD, is among the top researchers in the world who studies the molecular pathogenesis of multiple myeloma. His laboratory is focused on understanding the molecular events that lead to the development of MGUS and its progression to multiple myeloma. The research of Dr. Bergsagel and his colleagues has identified important subtypes of multiple myeloma that respond differently to treatment, are associated with different survival rates and form the basis for a risk-adapted approach to therapy. Using insights gained from an understanding of the genetic events that lead to the development of multiple myeloma, Dr. Bergsagel’s team have generated a mouse model of the disease. This model is being used to screen novel agents for their anti-myeloma activity. Dr. Bergsagel’s team have cloned more than 35 translocation breakpoints and identified five frequent translocation partners that are present in almost one-half of patients with multiple myeloma. They are now working to identify and clone various translocation breakpoints in order to clarify their roles in the development of multiple myeloma. Another focus is on the MYC oncogene that appears in some patients to cause the progression of MGUS to myeloma. Prior to joining the faculty at the Mayo Clinic, Dr. Bergsagel was on the medical faculty of the University of Toronto and a Medical Staff Fellow at the National Cancer Institute. He was a junior resident at the Stanford University Medical Center, completed his internship at Sunnybrook Medical Centre, and received his MD from the University of Toronto. He is a member of the National Institutes of Health Basic Mechanisms of Cancer Therapeutics Study Section and the American Society for Clinical Investigations. His honors include lectureships at Ohio State University, Hammersmith Hospital in London, England, and the Daniel E. Bergsagel visiting professorship at the Ontario Cancer Institute in Canada. In 2009 he was honored with the Robert A. Kyle Mayo Clinic Distinguished Investigator Award.

Read Bio
The panelist Sarah Lee, MD
Sarah Lee, MD

Dr. Lee is a hematologist-oncologist who specializes in the care of patients with plasma cell disorders. Before joining SCCA, she completed a fellowship in hematology-oncology at the Cleveland Clinic. Her background also includes experience in researching novel therapies for multiple myeloma, amyloidosis, and other plasma cell disorders. What drew her to SCCA was the opportunity to participate in clinical research and to embrace a collaborative approach to medicine.

Read Bio
The panelist Sarah Holstein, MD, PhD
Sarah Holstein, MD, PhD

Dr. Holstein is a physician-scientist who specializes in the treatment of multiple myeloma and related plasma cell dyscrasias. Prior to joining the faculty at UNMC, Dr. Holstein served as a myeloma specialist at the Roswell Park Cancer Institute and the University of Iowa. Her laboratory is focused on gaining a better understanding of the pathophysiology of multiple myeloma and the development of novel therapeutic agents for multiple myeloma. Her laboratory research has received funding from such sources as the National Institutes of Health, the American Society of Hematology, and the PhRMA Foundation. Dr. Holstein is an active clinical investigator, and has been involved in clinical trials for patients with newly diagnosed myeloma, with relapsed/refractory disease, as well as in the post-transplant maintenance setting. She has written numerous peer-reviewed research articles as well as review articles and book chapters. She is a member of the Alliance Multiple Myeloma Committee and the NCCN Multiple Myeloma Panel.

Read Bio
The panelist Paramesewaran Hari, MD, MS
Paramesewaran Hari, MD, MS

Parameswaran Hari, MD, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief of the Division of Hematology and Oncology in the Department of Medicine. In 2013, Dr. Hari received the Grassroots Champion for Patient Access award from the Association of Community Cancer Centers for promoting clinical efforts in the field of blood cancers. Dr. Hari had fellowships in Internal Medicine and Hematology from the United Kingdom and Medical Oncology and Transplantation at the Medical College of Wisconsin. He earned his MD from the Jawaharlal Institute of Post Graduate Medicine in India and his MBBS from the University of Kerala in India.

Read Bio
The panelist Andrew Cowan, MD
Andrew Cowan, MD

Dr Cowan is an assistant professor at UW and Fred Hutch in the division of medical oncology where he focuses on care and research of patients with multiple myeloma and AL amyloidosis. His primary interests lie in helping bring new therapies to patients in the clinic, and helping improve understanding of the global state of multiple myeloma through research collaborations with colleagues abroad.

Read Bio
The panelist David Coffey
David Coffey

David Coffey, M.D. is a physician scientist at the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance. He specializes in the treatment of multiple myeloma including hematopoietic stem cell transplantation. His research interests are in integrating clinical data, genomics, and functional assays to predict clinical outcomes and inform treatment decisions for patients with multiple myeloma.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811